NR4A1 and breast cancer: [18F]FDHT has been employed for androgen receptor (AR) imaging, with a study by Venema et al. in postmenopausal hormone receptor-positive breast cancer patients showing the tracer’s ability to visualize tumors with a sensitivity of 91% and a specificity of 100%.